Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in pediatric pyruvate kinase deficiency without regular transfusions
NL-OMON60496Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mitapivat in pyruvate kinase deficiency (PKD), sponsored by Agios Pharmaceuticals. Primary endpoint: Hemoglobin response. Started Jul 2023; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NL-OMON60496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60496.